Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2011 May-Jun;5(3):209-10.
doi: 10.4161/cam.5.3.15258. Epub 2011 May 1.

Met and the microenvironment: new insights for ovarian cancer metastasis

Carole Sourbier  1
Affiliations
Comment

Met and the microenvironment: new insights for ovarian cancer metastasis

Carole Sourbier. Cell Adh Migr. 2011 May-Jun.

Abstract

Ovarian cancer often has few symptoms, which makes it difficult to detect at an early stage. Therefore, most of the women will already have metastasis at the time of diagnosis. In their search of undercovering the mechanisms underlying ovarian cancer invasion, AK Mitra and collaborators demonstrate that the fibronectin receptor (α5β1-integrin) can directly activate the receptor tyrosine kinase Met, independently of its ligand. By linking the extracellular matrix with Met activation, and the invasion of ovarian cancer cells, Mitra et al confirm the crucial role played by Met in ovarian cancer and open new perspectives in the development of ovarian cancer targeted therapies.

PubMed Disclaimer

Comment on

References

    1. Mitra AK, Sawada K, Tiwari P, Mui K, Gwin K, Lengyel E. Ligand-independent activation of Met by fibronectin and alpha(5)beta(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene. 2011;30:1566–1576. - PMC - PubMed
    1. Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, et al. Loss of E-cadherin promotes ovarian cancer metastasis via alpha5-integrin, which is a therapeutic target. Cancer Res. 2008;68:2329–2339. - PMC - PubMed
    1. Zillhardt M, Christensen JG, Lengyel E. An orally available small-molecule inhibitor of Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia. 2010;12:1–10. - PMC - PubMed
    1. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 2010;11:834–848. - PubMed
    1. Di Renzo MF, Olivero M, Katsaros D, Crepaldi T, Gaglia P, Zola P, et al. Overexpression of the Met/HGF receptor in ovarian cancer. Int J Cancer. 1994;58:658–662. - PubMed